FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2514972693> ?p ?o ?g. }

• W2514972693 endingPage "2959" @default.
• W2514972693 startingPage "2951" @default.
• W2514972693 abstract "Anti-angiogenesis is an important therapy for cancer treatment. Peptide HM-3 is an integrin antagonist with anti-angiogenic and antitumor activity. Previous research found that HM-3 at an effective dose inhibited tumor growth whereas at higher doses, the inhibitory effect gradually decreased. In the present study, three human tumor cell lines, human colorectal cancer cell (HCT-116) and human hepatic cancer cell (Hep G-2 and SMMC-7721), were selected and their interactions with HM-3 were compared with western blot and flow cytometric assays. The effect of HM-3 on the migration of two tumor cell lines (HCT-116 and Hep G-2) was also evaluated and a bell-shaped dose-efficacy curve was found for both cell lines. Furthermore, in vivo imaging in BALB/c nude mice confirmed that HM-3 had a short half-life and targeted the tumor tissue. Moreover, on an HCT-116 xenograft model in BALB/c nude mice, HM-3 at 3 mg/kg inhibited tumor growth with an inhibition rate of 71.5% (by tumor mass) whereas at 12 and 48 mg/kg, the inhibition rates were 59.2 and 36.0%, respectively. Immunohistochemistry analyses found that both sunitinib (60 mg/kg) and HM-3 (3 and 48 mg/kg) decreased microvascular density and increased percent of HIF-1α and VEGF expressing cells. The present study investigated the effect of tumor microenvironments on the antitumor effect of HM-3 and concluded that HM-3 inhibited angiogenesis and thereafter tumor growth by directly inhibiting HUVEC migration. The special dose-efficacy curves for antitumor effect and for cell migration inhibition were correlated. The present study also confirmed that the effective dose has to be strictly defined for better clinical applications of anti‑angiogenic drugs such as HM-3." @default.
• W2514972693 created "2016-09-16" @default.
• W2514972693 creator A5029512731 @default.
• W2514972693 creator A5047765221 @default.
• W2514972693 creator A5062407544 @default.
• W2514972693 creator A5071527157 @default.
• W2514972693 creator A5086342255 @default.
• W2514972693 date "2016-09-09" @default.
• W2514972693 modified "2023-09-27" @default.
• W2514972693 title "In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT-116 xenograft model in nude mice" @default.
• W2514972693 cites W147592962 @default.
• W2514972693 cites W1496165410 @default.
• W2514972693 cites W1573363574 @default.
• W2514972693 cites W1963810538 @default.
• W2514972693 cites W1964704299 @default.
• W2514972693 cites W1994952389 @default.
• W2514972693 cites W2016569548 @default.
• W2514972693 cites W2019236201 @default.
• W2514972693 cites W2021844666 @default.
• W2514972693 cites W2022512773 @default.
• W2514972693 cites W2026621524 @default.
• W2514972693 cites W2029773366 @default.
• W2514972693 cites W2039957677 @default.
• W2514972693 cites W2063220206 @default.
• W2514972693 cites W2070953753 @default.
• W2514972693 cites W2073684903 @default.
• W2514972693 cites W2080884813 @default.
• W2514972693 cites W2088056286 @default.
• W2514972693 cites W2091906493 @default.
• W2514972693 cites W2094371010 @default.
• W2514972693 cites W2099487193 @default.
• W2514972693 cites W2100837269 @default.
• W2514972693 cites W2105460573 @default.
• W2514972693 cites W2105677187 @default.
• W2514972693 cites W2107120406 @default.
• W2514972693 cites W2109110119 @default.
• W2514972693 cites W2117692326 @default.
• W2514972693 cites W2136397899 @default.
• W2514972693 cites W2138164563 @default.
• W2514972693 cites W2139511378 @default.
• W2514972693 cites W2140088548 @default.
• W2514972693 cites W2140859605 @default.
• W2514972693 cites W2324677651 @default.
• W2514972693 cites W2326760207 @default.
• W2514972693 cites W4250428608 @default.
• W2514972693 doi "https://doi.org/10.3892/or.2016.5077" @default.
• W2514972693 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32323854" @default.
• W2514972693 hasPublicationYear "2016" @default.
• W2514972693 type Work @default.
• W2514972693 sameAs 2514972693 @default.
• W2514972693 citedByCount "6" @default.
• W2514972693 countsByYear W25149726932017 @default.
• W2514972693 countsByYear W25149726932019 @default.
• W2514972693 countsByYear W25149726932021 @default.
• W2514972693 crossrefType "journal-article" @default.
• W2514972693 hasAuthorship W2514972693A5029512731 @default.
• W2514972693 hasAuthorship W2514972693A5047765221 @default.
• W2514972693 hasAuthorship W2514972693A5062407544 @default.
• W2514972693 hasAuthorship W2514972693A5071527157 @default.
• W2514972693 hasAuthorship W2514972693A5086342255 @default.
• W2514972693 hasBestOaLocation W25149726931 @default.
• W2514972693 hasConcept C104317684 @default.
• W2514972693 hasConcept C121608353 @default.
• W2514972693 hasConcept C126322002 @default.
• W2514972693 hasConcept C150903083 @default.
• W2514972693 hasConcept C185592680 @default.
• W2514972693 hasConcept C202751555 @default.
• W2514972693 hasConcept C207001950 @default.
• W2514972693 hasConcept C2776415932 @default.
• W2514972693 hasConcept C2780278673 @default.
• W2514972693 hasConcept C2780394083 @default.
• W2514972693 hasConcept C502942594 @default.
• W2514972693 hasConcept C54355233 @default.
• W2514972693 hasConcept C55493867 @default.
• W2514972693 hasConcept C62112901 @default.
• W2514972693 hasConcept C71924100 @default.
• W2514972693 hasConcept C81885089 @default.
• W2514972693 hasConcept C86803240 @default.
• W2514972693 hasConceptScore W2514972693C104317684 @default.
• W2514972693 hasConceptScore W2514972693C121608353 @default.
• W2514972693 hasConceptScore W2514972693C126322002 @default.
• W2514972693 hasConceptScore W2514972693C150903083 @default.
• W2514972693 hasConceptScore W2514972693C185592680 @default.
• W2514972693 hasConceptScore W2514972693C202751555 @default.
• W2514972693 hasConceptScore W2514972693C207001950 @default.
• W2514972693 hasConceptScore W2514972693C2776415932 @default.
• W2514972693 hasConceptScore W2514972693C2780278673 @default.
• W2514972693 hasConceptScore W2514972693C2780394083 @default.
• W2514972693 hasConceptScore W2514972693C502942594 @default.
• W2514972693 hasConceptScore W2514972693C54355233 @default.
• W2514972693 hasConceptScore W2514972693C55493867 @default.
• W2514972693 hasConceptScore W2514972693C62112901 @default.
• W2514972693 hasConceptScore W2514972693C71924100 @default.
• W2514972693 hasConceptScore W2514972693C81885089 @default.
• W2514972693 hasConceptScore W2514972693C86803240 @default.
• W2514972693 hasIssue "5" @default.
• W2514972693 hasLocation W25149726931 @default.
• W2514972693 hasOpenAccess W2514972693 @default.

• next